Eupry

eupry.com · 12 vendors

Resilience scores

Technology vendors

Insights

Last updated 2026-06-09 · revision 2

12 direct vendors, 221 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 6/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Eupry's migration readiness is assessed at 55, placing it in the medium readiness category. A significant strength is its cloud-native foundation, with AWS as its internal tech stack and core products like "Continuous Mapping and Monitoring (CMM) Software" being cloud-based. The absence of specified data residency requirements offers substantial flexibility for potential migrations. Furthermore, modern security practices such as AES-256 encryption, TLS 1.3, Zero-Trust Authentication, and Role-Based Access Control are well-aligned with cloud environments and facilitate secure transitions. However, several factors present considerable challenges. The highly regulated environment, with stringent GxP, FDA 21 CFR Part 11, and ISO 17025 compliance requirements, will introduce significant complexity, cost, and validation effort to any migration, potentially extending timelines. The lack of data regarding Eupry's financial stability (revenue concentration, growth history) makes it impossible to assess its capacity to fund a potentially complex migration. Crucially, the "Vendor Lock-in Risk" is unknown. If Eupry has high lock-in with its existing (assumed) vendors for 17 services, this could severely impede migration flexibility and increase costs. The contradiction in the provided vendor data ("Total Vendors: 0" vs. listed third-party services and vendor geographic diversity) highlights an information gap that impacts a precise assessment of vendor-related migration challenges.

Compliance

5 in-scope frameworks identified; showing 3.

SOC 2 (source) — Assessment Required

As a cloud-based service provider handling sensitive customer data for regulated industries, SOC2 compliance is highly relevant for Eupry. They provide SaaS temperature monitoring solutions with data processing and storage, making SOC2 Type II reports valuable for customer assurance. Medium risk because while they have strong security practices (ISO 27001, AWS hosting, encryption), lack of explicit SOC2 evidence could impact customer confidence and sales, especially with enterprise pharmaceutical clients who typically require SOC2 reports from vendors.

Evidence: https://eupry.com/certifications-accreditations/, https://eupry.com/

HIPAA (source) — Assessment Required

Eupry serves healthcare organizations and hospitals, potentially handling Protected Health Information (PHI) through their temperature monitoring systems in healthcare facilities. While not a traditional healthcare provider, their services in hospital temperature monitoring could involve PHI exposure. Medium risk due to potential indirect HIPAA obligations through healthcare customers and the need for Business Associate Agreements (BAAs). The company's strong security practices (ISO 27001, encryption) suggest technical readiness, but formal HIPAA compliance assessment is needed.

Evidence: https://eupry.com/solutions/hospital-temperature-monitoring/, https://eupry.com/certifications-accreditations/

GDPR (source) — Compliant

While Eupry is headquartered in Denmark (EU) and explicitly states GDPR compliance, the medium risk reflects ongoing compliance maintenance requirements. As a Danish company processing personal data of EU residents and global customers, GDPR compliance is mandatory. The company demonstrates good practices with dedicated privacy notices and explicit GDPR compliance statements, but continuous monitoring is required for data processing activities across multiple jurisdictions.

Evidence: https://eupry.com/certifications-accreditations/, https://eupry.com/privacy/

Financials

Three-year financials

Financial Resilience Score: 6/10

Eupry ApS shows qualitative signs of solid financial resilience despite undisclosed financials. The company has built a blue-chip, regulated customer base including Novo Nordisk, AstraZeneca, Baxter, FedEx, DHL, DSV, and NHS. Customers in pharma/biotech and pharma-logistics typically exhibit very low churn once embedded in their GxP/GDP quality systems, providing recurring revenue stability through SaaS subscriptions, calibration services, and audit reporting. The company benefits from a strong regulatory moat through ISO 17025, ISO 27001, FDA 21 CFR Part 11 compliance, and ILAC-MRA accreditations that are difficult and costly for competitors to replicate. International diversification across 50 countries with offices in Denmark, US, UK, and Ireland reduces geographic concentration risk. Patented on-the-wall calibration technology provides differentiation versus established competitors like Vaisala, Ellab, and Rotronic. However, as a private small/medium-sized company likely still in growth/investment phase, profitability is not confirmed and many Danish SaaS/hardware scale-ups continue to post losses while scaling. Hardware working-capital intensity, strong competition from larger-balance-sheet players, potential customer concentration with large pharma accounts, and FX exposure (DKK reporting against USD/GBP/EUR markets) all create meaningful risks. The score reflects strong qualitative positioning offset by unverified financial figures and typical scale-up risks.

Key strengths: Blue-chip regulated customer base (Novo Nordisk, AstraZeneca, Baxter, FedEx, DHL, NHS), Recurring SaaS + hardware + calibration revenue model with low churn, Strong regulatory moat (ISO 17025, ISO 27001, FDA 21 CFR Part 11, ILAC-MRA, IATA CEIV Pharma), International footprint across 50 countries with offices in DK, US, UK, IE, Patented on-the-wall calibration technology differentiation, >1,000 customers across >6,000 monitored locations

Risk factors: Private SMB likely still in growth/investment phase; profitability unconfirmed, Hardware working-capital intensity and component-supply cycle exposure, Strong competition from larger players (Vaisala, Ellab, Rotronic/PST, ELPRO, testo, Tutela), Potential customer concentration risk with large pharma accounts, FX exposure between DKK reporting and USD/GBP/EUR markets

Revenue by geography

Revenue by product/service

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report